Bradmer initiates enrollment in Phase III GLASS-ART Trial in primary glioblastoma multiforme

31-Jul-2008

Bradmer Pharmaceuticals Inc. announced that it has initiated enrollment in the Phase III GLASS-ART Trial evaluating Neuradiab(TM), a monoclonal antibody conjugated to Iodine-131, as a front-line therapy for primary glioblastoma multiforme (GBM). The first patient was enrolled at the Preston Robert Tisch Brain Tumor Center at Duke University under direction of Dr. David Reardon as Principal Investigator.

The Phase III GLASS-ART Trial derives its name from its description: GBM Locoregional Agent Survival Study - Antitenascin Radiolabeled antibody Therapy Trial. The study is designed to determine the survival benefit derived from, and safety of, adding Neuradiab(TM) to the current standard of care therapy, consisting of surgery, radiation and adjuvant chemotherapy (temozolomide), for patients diagnosed with primary glioblastoma mulitforme. The randomized trial will enroll up to 760 patients at leading treatment centers across the United States.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance